Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Business Wire•02/10/2026•09:00 ET
0
Key Highlights
- ➤AGEN accepted two BOT+BAL research posters for SITC 2026 presentations
- ➤BOT+BAL poster will detail long-term survivors with refractory MSS metastatic colorectal cancer
- ➤agenT-797 plus BOT+BAL research will show tumor-cell killing in colorectal cancer liver metastases model
- ➤SITC 2026 presentations scheduled November 7, 2026, in Phoenix, Arizona
Expert Statements
Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center
“Clinical features of long-term survivors treated with next-generation anti-CTLA-4 (botensilimab) plus anti-PD-1 (balstilimab) in refractory microsatellite-stable metastatic colorectal cancer”
Shanmugarajan Krishnan, Ph.D., M.S., B.S., Agenus Inc.
“AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases”
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.
Get started
Create a free account to read the full story.